Generic Name: upadacitinib
Brand Name: Rinvoq
Therapeutic Area: atopic dermatitis
Indications: Rinvoq is indicated for the treatment of adults and adolescents 12 years and older with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. Rinvoq can be used with or without topical corticosteroids
Manufacturer Requested Reimbursement Criteria1: For the treatment of patients aged 12 years and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and/or who are refractory to or ineligible for systemic immunosuppressant therapies (i.e., due to contraindications, intolerance, or need for long-term treatment).
Submission Type: Initial
Project Status: Pending
Call for patient/clinician input open: March 15, 2021
Call for patient/clinician input closed: May 7, 2021
Anticipated Date: April 13, 2021
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.